Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, open-label study to investigate the effectiveness and safety of AOP Landiolol in controlling supraventricular tachycardia in pediatric patients (LANDI-PED).

Next Previous
Trial Profile

A multicenter, open-label study to investigate the effectiveness and safety of AOP Landiolol in controlling supraventricular tachycardia in pediatric patients (LANDI-PED).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Landiolol (Primary)
  • Indications Paroxysmal supraventricular tachycardia; Supraventricular tachycardia
  • Focus Registrational; Therapeutic Use
  • Acronyms LANDI-PED
  • Sponsors AOP Orphan Pharmaceuticals AG

Most Recent Events

  • 16 Apr 2026 According to an AOP Health media release, company announced that the U.S. Food and Drug Administration (FDA) has approved RAPIBLYK (landiolol) for use in pediatric patients (from birth to <18 years of age) with supraventricular tachycardia (SVT).
  • 05 Feb 2025 Status changed from recruiting to completed, according to results published in the Europace.
  • 05 Feb 2025 Results published in the Europace.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top